Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab for Improving Tolerability of Immunotherapy in Allergic Asthma
NCT00267202Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2005
- Primary completion
- Jan 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in allergic asthma comparing Omalizumab + SIT with Placebo + SIT (2 arms). Primary endpoint: Number of Participants With Systemic Allergic Reactions (SAR) to Specific Immunotherapy (SIT) at 26 weeks. Started Dec 2005; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT00267202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00267202.